Press Releases
Feb. 10, 2021 Bioasis Announces Shares for Debt Transaction
NEW HAVEN, Conn., Feb. 10, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers… Read more »
Jan. 29, 2021 Bioasis Announces $200,000 Non-Brokered Private Placement
GUILFORD, Conn., Jan. 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and… Read more »
Jan. 27, 2021 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020
GUILFORD, Conn., Jan. 27, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3 TM?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced… Read more »
Jan. 22, 2021 Bioasis Announces Stock Option Grant
GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative… Read more »
Jan. 4, 2021 Bioasis to Present at Upcoming Industry Conferences
GUILFORD, Conn., Jan. 04, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. – Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high… Read more »
Dec. 10, 2020 Bioasis Announces Annual General Meeting Results
GUILFORD, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »
Dec. 3, 2020 Platform Technology – Overcoming the Challenges of Drug Brain Delivery With a Novel Brain Delivery Vector
Latest publication on Bioasis’ leading BBB drug delivery technology by Dr. Mei Mei Tian, our Head of External Research.
Nov. 10, 2020 Bioasis Announces Annual General Meeting Details
GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »
Nov. 3, 2020 Bioasis Announces Sale of Royalty Interest in Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance to XOMA Corporation
GUILFORD, Conn., Nov. 03, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »
Oct. 29, 2020 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2020
GUILFORD, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »